Long-term survival results of a randomized phase iii trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1466-1472

  Bellmunt, J ^a   Fougeray, R ^b   Rosenberg, J E ^c   von der Maase, H ^d   Schutz, F A ^c   Salhi, Y ^b   Culine, S ^e   Choueiri, T K ^c  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Rigshospitalet   (Denmark)

^e Hôpita Henri Mondor ^*  (France)

Author keywords

Antineoplastic; Bladder neoplasms; Survival analysis; Transitional cell carcinoma; Urologic tumor

Indexed keywords

PLATINUM DERIVATIVE; VINFLUNINE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TRANSITIONAL CELL CARCINOMA;

ANTINEOPLASTIC; BLADDER NEOPLASMS; SURVIVAL ANALYSIS; TRANSITIONAL CELL CARCINOMA; UROLOGIC TUMOR;

AGED; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATINUM COMPOUNDS; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE; URINARY BLADDER NEOPLASMS; UROTHELIUM; VINBLASTINE;

EID: 84878442860     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt007     Document Type: Article

References (19)

1. Bellmunt J, Von der Maase H, Mead GM et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2012; 30(10): 1107-1113.
2. Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64(12): 2448-2458.
3. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18(17): 3068-3077.
4. Lorusso V, Pollera CF, Antimi M et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998; 34 (8): 1208-1212.
5. McCaffrey JA, Hilton S, Mazumdar M et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15 (5): 1853-1857.
6. Sweeney CJ, Roth BJ, Kabbinavar FF et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006; 24(21): 3451-3457.
7. Vaughn DJ, Broome CM, Hussain M et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20(4): 937-940.
8. Fechner G, Siener R, Reimann M et al. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract 2006; 60(1): 27-31.
9. Kanai K, Kikuchi E, Ohigashi T et al. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatinbased chemotherapy. Int J Clin Oncol 2008; 13(6): 510-514.
10. Kouno T, Ando M, Yonemori K et al. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol 2007; 52(4): 1115-1122.
11. Meluch AA, Greco FA, Burris HA, 3rd et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001; 19(12): 3018-3024.
12. Sternberg CN, Calabro F, Pizzocaro G et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001; 92(12): 2993-2998.
13. Suyama T, Ueda T, Fukasawa S et al. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol 2009; 39(4): 244-250.
14. Bellmunt J, Theodore C, Demkov T et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinumcontaining regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27(27): 4454-4461.
15. Bellmunt J, Choueiri TK, Fougeray R et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28(11): 1850-1855.
16. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol 1991; 9(1): 191-192.
17. Choueiri TK, Ross RW, Jacobus S et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 2012; 30(5): 507-512.
18. Albers P, Siener R, Hartlein M et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie 2002; 25(1): 47-52.
19. Jessen C, Agerbaek M, Von Der Maase H. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy. Acta Oncol 2009; 48(3): 411-417.